Compare RIOT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIOT | LEGN |
|---|---|---|
| Founded | 2000 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9B | 5.9B |
| IPO Year | 2002 | 2020 |
| Metric | RIOT | LEGN |
|---|---|---|
| Price | $27.12 | $27.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $25.43 | ★ $61.33 |
| AVG Volume (30 Days) | ★ 16.7M | 2.2M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $647,435,000.00 | N/A |
| Revenue This Year | N/A | $42.68 |
| Revenue Next Year | $24.12 | $30.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 71.89 | N/A |
| 52 Week Low | $7.99 | $16.24 |
| 52 Week High | $28.54 | $45.30 |
| Indicator | RIOT | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 72.16 | 52.88 |
| Support Level | $12.26 | $25.01 |
| Resistance Level | N/A | $29.69 |
| Average True Range (ATR) | 1.37 | 1.99 |
| MACD | 0.18 | -0.29 |
| Stochastic Oscillator | 82.23 | 46.92 |
Riot Platforms Inc is a vertically integrated digital infrastructure company principally engaged in developing and optimizing its large-scale power assets. The Company's business centers on enhancing its electrical infrastructure and deploying it across two complementary platforms: (i) Bitcoin Mining and (ii) scalable data center solutions designed to support non-mining workloads. The company's segments include Bitcoin Mining and Engineering. The Bitcoin Mining segment generates revenue from the Bitcoin the Company earns through its Bitcoin Mining activities. The Engineering segment generates revenue through customer contracts for custom engineered electrical products. It generates the majority of its revenue from the Bitcoin Mining segment.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.